From molecular profiling and biomarkers to targeted therapies and AI, advances in breast cancer research are enabling more personalized approaches to detection and treatment.
Every October, Breast Cancer Awareness Month 2026 brings renewed attention to one of the most commonly diagnosed cancers affecting women worldwide. The month is an opportunity to increase awareness of breast cancer risk and symptoms, encourage appropriate screening and early diagnosis, support people living with the disease and highlight research that continues to reshape breast cancer care.
It is a substantial challenge. According to the World Health Organization (WHO), an estimated 2.4 million women were diagnosed with breast cancer worldwide in 2024 and approximately 694,000 died from the disease. Breast cancer was the most common cancer among women in 164 of 186 countries that year.
In breast cancer, differences in tumour biology, stage, inherited risk, access to care and individual circumstances can all influence diagnosis and treatment. The focus now, is on detecting disease earlier and matching treatment more precisely to the characteristics of each cancer.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Breast Cancer Risk Extends Beyond Family History
Family history is often associated with breast cancer risk, but most people diagnosed with breast cancer do not have a known family history of the disease. The WHO estimates that approximately 80 percent of breast cancers occur in women with no specific risk factors other than sex and age.
Risk increases with age, while other factors can include obesity, alcohol use, tobacco use, reproductive history, previous radiation exposure and postmenopausal hormone therapy. Certain inherited genetic variants can also substantially increase risk. Among the best known are pathogenic variants in BRCA1 and BRCA2, along with other genes such as PALB2.
Understanding risk affects decisions around screening and prevention. People with a strong family history or known inherited susceptibility may be offered additional surveillance, genetic counselling or risk-reduction strategies based on their individual circumstances.
Breast cancer can also occur in men, although it is uncommon. The WHO estimates that approximately 0.5 to 1 percent of breast cancers occur in men, reinforcing that breast changes warrant attention regardless of sex.
Recognizing Changes and Detecting Breast Cancer Earlier
Early detection remains one of the most important components of breast cancer control. The WHO notes that breast cancers are more likely to be successfully treated when they are small and have not spread to nearby lymph nodes.
Possible symptoms can include a breast lump or thickening, changes in breast size or shape, skin dimpling or redness, changes involving the nipple or areola and abnormal or bloody nipple discharge.
The National Cancer Institute (NCI) notes that mammography is an effective breast cancer screening test and that MRI and ultrasound are also used for detection, although not as routine screening tools for people at average risk.
Screening recommendations can differ by country, age and individual risk. That makes risk-informed discussions with healthcare professionals important, particularly for people with a family history, known genetic susceptibility or other factors that may place them at higher risk.
From One Diagnosis to Multiple Breast Cancer Subtypes
A breast cancer diagnosis increasingly serves as the beginning of a more detailed biological assessment. Tumors may be evaluated for hormone receptors such as estrogen and progesterone receptors, HER2 expression and genomic or molecular features that can help guide treatment.
Therapies that are effective for one subtype may have little benefit in another. Hormone receptor-positive cancers, for example, may respond to endocrine therapy, while HER2-positive cancers can be treated with therapies directed against HER2. Triple-negative breast cancer lacks estrogen receptor, progesterone receptor and HER2 expression, creating a different set of therapeutic challenges and opportunities.
Targeted Therapies Are Expanding Treatment Options
Breast cancer treatment can include surgery, radiation therapy, chemotherapy, endocrine therapy, targeted therapy and immunotherapy. NCI highlights multiple targeted approaches now used or being studied in breast cancer, including monoclonal antibodies, antibody-drug conjugates (ADCs) and small-molecule drugs that interfere with pathways cancer cells use to grow and survive.
ADCs combine an antibody directed toward a tumor-associated target with a cytotoxic payload, providing a way to deliver an anticancer drug to cells expressing that target.
Research involving HER2-low and HER2-ultralow disease has expanded the populations that may benefit from HER2-directed ADCs. NCI notes that research demonstrating improved outcomes with trastuzumab deruxtecan contributed to expanded use in some people with metastatic breast cancer with low or very low HER2 expression.
Other targeted strategies are being developed around alterations in pathways such as PI3K and AKT, while CDK4/6 inhibitors have changed treatment for many patients with hormone receptor-positive breast cancer.
Research Is Pushing Breast Cancer Detection and Treatment Further
Research is also exploring how new technologies could improve the way breast cancer is detected, classified and monitored. AI is one area of growing investigation. NCI-supported research includes work using AI to identify patients with ductal carcinoma in situ who may be at greater risk of disease progression and could therefore require more intensive treatment.
Researchers are also studying circulating tumor DNA, blood-based biomarkers and other minimally invasive approaches that could eventually complement existing tools for detecting disease or monitoring treatment response. Genomic testing is also helping researchers understand which tumors are most likely to recur and which biological pathways may provide useful therapeutic targets.
The Global Burden Is Also a Question of Equity
According to WHO, about one in 12 women in higher-income settings will be diagnosed with breast cancer during their lifetime, compared with about one in 27 women in lower-resource settings. Despite fewer diagnoses, women in lower-resource settings face a disproportionately high risk of dying from the disease.
In 2021, WHO established the Global Breast Cancer Initiative with a goal of reducing global breast cancer mortality by 2.5 percent per year. WHO estimates that achieving this target could avert 2.5 million breast cancer deaths globally by 2040.
The initiative centers on three pillars: health promotion for early detection, timely diagnosis and comprehensive breast cancer management.
Breast Cancer Awareness Month 2026: Turning Awareness into Action
Research has transformed breast cancer care over recent decades, and the treatment landscape continues to evolve through advances in molecular profiling, targeted therapies, ADCs, immunotherapy, imaging and AI. Yet progress depends on more than developing new technologies. Earlier diagnosis, timely access to effective treatment and equitable delivery of care remain central to reducing breast cancer mortality.
Breast Cancer Awareness Month 2026 is an opportunity not only to raise awareness, but also to recognize the broader goal behind it: ensuring that advances in prevention, detection and treatment translate into longer and healthier lives for more people affected by breast cancer. Earlier diagnosis, timely access to effective treatment and equitable delivery of care remain central to reducing breast cancer mortality.
Breast Cancer Awareness Month 2026 is an opportunity not only to raise awareness, but also to ensure that advances in prevention, detection and treatment translate into longer and healthier lives for more people affected by breast cancer.
Join or login to leave a comment
JOIN LOGIN